

1st May 2014

Proposal to list various radiological contrast media

PHARMAC is seeking feedback on proposals relating to provisional agreements with a number of suppliers for the supply of contrast media.

Summary of the proposals

Provisional agreements for listing contrast media have been reached with the following suppliers:

- **Bayer New Zealand Limited**
 - gadotexate disodium (Primovist)
 - meglumine iotrexate (Biliscopin)
 - gadobutrol (Gadovist)
 - sodium and meglumine amidotrizoate (Gastrografin)
 - meglumine gadopentate (Magnevist)
- **GE Healthcare Limited**
 - gadodiamide (Omniscan)
 - iohexol (Omnipaque)
 - iodixanol (Visipaque)
- **Global Medical Solutions (NZ) Limited**
 - perflutren (Definity)
- **Obex Medical Limited**
 - Gadoteric acid (Dotarem)
 - iodised oil (Lipiodol Ultra Fluid)
 - patent blue V (Patent Blue V)

Omnipaque, Visipaque and Definity would be awarded Hospital Sole Supply status for the non-ionic monomer, non-ionic dimer and ultrasound contrast media markets respectively from 1 September 2014.

The following products would be delisted from 1 September 2014:

- all presentations of iomeprol;
- all presentations of iopromide;
- iotrolan inj 240 mg per ml, 10 ml vial;
- diatrizoate meglumine with diatrizoate sodium inj 146 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle; and
- diatrizoate meglumine with diatrizoate sodium inj 370 mg with sodium amidotrizoate 100 mg per ml, 50 ml bottle.

The background to and details of the proposal can be found on the following pages.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Friday, 16th May 2014** to:

Christine Chapman
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

Email: Christine.chapman@pharmac.govt.nz
Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld. PHARMAC will give due consideration to any such request.

Background

In September 2013 PHARMAC released a Request for Proposals (RFP) for supply of radiological contrast media for the DHB Hospitals. The RFP document can be found at the following link:

<http://www.pharmac.health.nz/assets/rfp-2013-10-02-radiological-contrast-media.pdf>

The timetable for the RFP was amended on the 18th December 2013 and further detail can be found at:

<http://www.pharmac.health.nz/assets/notification-2013-12-18-rcm-rfp-amended-timeline.pdf>

The proposed listings and amendments are as a result of this RFOP process.

Please note: PHARMAC is in discussion with Regional Healthcare for supply of gadobenic acid (Multihance), diatrizoate sodium (Ioscan) and various barium presentations following the RFP.

Details of the proposals

Bayer New Zealand Limited

A provisional agreement with Bayer New Zealand Ltd would result in the following listings and amendments.

- new listings in Part II of Section H of the Pharmaceutical Schedule from 1 July 2014 (prices are ex-manufacturer and excluding GST):

Chemical	Presentation	Brand	Pack size	Price
Gadoxetate disodium	Inj 181.43 mg per mL (equivalent to 0.25 mmol per ml), 10 ml syringe	Primovist	1	\$300.00
Meglumine iotrexate	Inj 105 mg meglumine iotrexate, 100 ml bottle	Biliscopin	1	\$150.00

- amended listings in Part II of Section H from 1 July 2014 as follows (prices are ex-manufacturer and excluding GST):

Chemical	Presentation	Brand	Pack size	Current price	Proposed price
Gadobutrol	Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml syringe	Gadovist	5	\$253.10	\$180.00
Gadobutrol	Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml vial	Gadovist	10		\$700.00
Meglumine diatrizoate with sodium amidotrizoate	Oral liq 660 mg per ml with 100 mg per ml sodium amidotrizoate, 100 ml bottle	Gastrografin	1	\$21.00	\$22.50
Meglumine gadopentate	Inj 469 mg per ml (equivalent to 0.5 mmol per ml), 10 ml syringe	Magnevist	5	\$92.00	\$95.00
Meglumine gadopentate	Inj 469 mg per ml (equivalent to 0.5 mmol per ml), 10 ml vial	Magnevist	10	\$184.00	\$185.00

- The following products would be delisted from Part II of Section H of the Pharmaceutical Schedule from 1 July 2014 as they are no longer available from the manufacturer:

Chemical	Presentation	Brand	Pack size	Price
Meglumine	Inj 370 mg with			

diatrizoate with sodium amidotrizoate	sodium amidotrizoate 100 mg per ml, 50 ml bottle			
Meglumine diatrizoate with sodium amidotrizoate	Inj 146 mg per ml sodium amidotrizoate with 40 mg per ml, 250 ml bottle	Gastrografin	10	\$210.00

- All pharmaceuticals supplied by Bayer New Zealand Limited under this provisional agreement would have delisting protection up to and including 30 June 2017.

GE Healthcare Limited

A provisional agreement with GE Healthcare Limited would result in the following:

- amendments to listings in Part II of Section H of the Pharmaceutical Schedule from 1 July 2014 (all prices are ex-manufacturer and exclusive of GST):

Chemical	Presentation	Brand	Pack size	Current price	Proposed Price
Gadodiamide	Inj 287 mg per ml, 5 ml vial	Omniscan	10		\$120.00
Gadodiamide	Inj 287 mg per ml, 10 ml syringe	Omniscan	10	\$220.00	\$200.00
Gadodiamide	Inj 287 mg per ml, 10 ml vial	Omniscan	10	\$180.00	\$170.00
Gadodiamide	Inj 287 mg per ml, 15 ml syringe	Omniscan	10	\$330.00	\$320.00
Iohexol	Inj 240 mg per ml, 50 ml bottle	Omnipaque	10	\$77.80	\$75.00
Iohexol	Inj 300 mg per ml, 20 ml bottle	Omnipaque	10		\$57.00
Iohexol	Inj 300 mg per ml, 50 ml bottle	Omnipaque	10	\$77.80	\$75.00
Iohexol	Inj 300 mg per ml, 100 ml bottle	Omnipaque	10	\$155.60	\$150.00
Iohexol	Inj 350 mg per ml, 20 ml bottle	Omnipaque	10		\$59.00
Iohexol	Inj 350 mg per ml, 50 ml bottle	Omnipaque	10	\$77.80	\$75.00
Iohexol	Inj 350 mg per ml, 75 ml bottle	Omnipaque	10	\$116.70	\$114.00
Iohexol	Inj 350 mg per ml, 100 ml bottle	Omnipaque	10	\$155.60	\$150.00
Iohexol	Inj 350 mg per ml, 200 ml bottle	Omnipaque	10	\$311.16	\$290.00
Iodixanol	Inj 270 mg per ml, 50 ml bottle	Visipaque	10	\$223.50	\$220.00
Iodixanol	Inj 270 mg per ml, 100	Iodixanol	10	\$447.00	\$430.00

	ml bottle				
Iodixanol	Inj 320 mg per ml , 50 ml bottle	Iodixanol	10	\$223.50	\$220.00
Iodixanol	Inj 320 mg per ml , 100 ml bottle	Iodixanol	10	\$447.00	\$430.00
Iodixanol	Inj 320 mg per ml , 200 ml bottle	Iodixanol	10	\$894.00	\$850.00

- Visipaque and Omnipaque would have Hospital Sole Supply status from 1 July 2014 to 30 June 2017 in the non-ionic dimer and non-ionic monomer markets respectively. A 5% DV limit would apply to both.
- All presentations of iomeprol and iopromide would be delisted from Part II of Section H of the Pharmaceutical Schedule from 1 July 2014 as a result of awarding Hospital supply Status to Omnipaque and Visipaque.

Global Medical Solutions (NZ) Limited

- A provisional agreement with Global Medical Solutions (NZ) Limited would result in the listing of perflutren (Definity) in Part II of Section H of the Pharmaceutical Schedule from 1 July 2014 as follows (prices are ex-manufacturer, excluding GST):

Chemical	Presentation	Brand	Pack size	Price
Perflutren	Inj 1.1 mg per ml, 1.5 ml vial	Definity	1	\$180.00
Perflutren	Inj 1.1 mg per ml, 1.5 ml vial	Definity	4	\$720.00

- Definity would have Hospital Sole Supply status from 1 July 2014 to 30 June 2017 in the Ultrasound contrast media market. A 5% DV limit would apply.

Obex Medical Limited

A provisional agreement with Obex Medical Limited would result in the following listings and amendments:

- new listing of two new presentations of gadoteric acid in Part II of Section H of the Pharmaceutical Schedule (prices are ex-manufacturer excluding GST) from 1 July 2014 as follows:

Chemical	Presentation	Brand	Pack size	Price
Gadoteric acid	Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml vial	Dotarem	1	\$12.50
Gadoteric acid	Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml vial	Dotarem	1	\$35.00

- amendments in Part II of Section H of the Pharmaceutical Schedule from 1 July 2014 (prices are ex-manufacturer excluding GST):

Chemical	Presentation	Brand	Pack size	Price
Gadoteric acid	Inj 279.32 mg/ml (0.5 mmol/ml), 10 ml vial	Dotarem	1	\$23.50
Gadoteric acid	Inj 279.32 mg/ml (0.5 mmol/ml), 20 ml vial	Dotarem	1	\$47.00
Gadoteric acid	Inj 279.32 mg/ml (0.5 mmol/ml), 10 ml syringe	Dotarem	1	\$25.00
Gadoteric acid	Inj 279.32 mg/ml (0.5 mmol/ml), 15 ml syringe	Dotarem	1	\$41.00
Gadoteric acid	Inj 279.32 mg/ml (0.5 mmol/ml), 20 ml syringe	Dotarem	1	\$55.00
Iodised Oil	Inj 480 mg iodine per ml, 10 ml vial	Lipiodol	1	\$143.00
Patent blue V	Inj 2.5%, 2 ml ampoule	Patent Blue V	5	\$440.00

- All pharmaceuticals supplied by Obex Medical Limited under this provisional agreement would have delisting protection up to and including 30 June 2017.